1
|
Sorolla A, Wang E, Clemons TD, Evans CW, Plani-Lam JH, Golden E, Dessauvagie B, Redfern AD, Swaminathan-Iyer K, Blancafort P. Triple-hit therapeutic approach for triple negative breast cancers using docetaxel nanoparticles, EN1-iPeps and RGD peptides. Nanomedicine 2019; 20:102003. [PMID: 31055077 DOI: 10.1016/j.nano.2019.04.006] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/19/2018] [Revised: 04/11/2019] [Accepted: 04/11/2019] [Indexed: 12/20/2022]
Abstract
Triple negative breast cancers (TNBC) are aggressive malignancies for which chemotherapy is the only treatment option. Many TNBC acquire chemotherapy resistance, notably docetaxel, which has been associated with the overexpression of transcription factors (TFs), such as ENGRAILED1 (EN1). Here, we have developed a tumor delivery system for docetaxel-PGMA-PAA-nanoparticles and interference peptides designed to specifically inhibit EN1 (EN1-iPeps). To promote tumor specific targeting, we functionalized these nanoparticles with EN1-iPeps engineered with RGD sequences. We found that these peptides reduce cell viability and induce apoptosis in TNBC cells with negligible effects on normal cells (EN1-). Moreover, EN1-RGD-iPeps-mediated nanoparticle internalization into breast cancer cells was via integrins and intravenous injection of this nanoformulation increased tumor accumulation. Furthermore, docetaxel nanoparticles functionalized with EN1-RGD-iPeps significantly reduced TNBC growth both in vitro and in vivo without showing toxicity. Our results suggest that this targeted nanoformulation represents a new and safe therapeutic approach for chemoresistant TNBCs.
Collapse
Affiliation(s)
- Anabel Sorolla
- Cancer Epigenetics, Harry Perkins Institute of Medical Research Nedlands, WA 6009, Australia; School of Human Sciences, The University of Western Australia Crawley, WA 6009, Australia.
| | - Edina Wang
- Cancer Epigenetics, Harry Perkins Institute of Medical Research Nedlands, WA 6009, Australia; School of Human Sciences, The University of Western Australia Crawley, WA 6009, Australia
| | - Tristan D Clemons
- School of Molecular Science, The University of Western Australia, Crawley, WA 6009, Australia
| | - Cameron W Evans
- School of Molecular Science, The University of Western Australia, Crawley, WA 6009, Australia
| | - Janice Hc Plani-Lam
- Cancer Epigenetics, Harry Perkins Institute of Medical Research Nedlands, WA 6009, Australia; School of Human Sciences, The University of Western Australia Crawley, WA 6009, Australia
| | - Emily Golden
- Cancer Epigenetics, Harry Perkins Institute of Medical Research Nedlands, WA 6009, Australia; School of Human Sciences, The University of Western Australia Crawley, WA 6009, Australia
| | - Ben Dessauvagie
- Division of Pathology and Laboratory Medicine, Medical School, The University of Western Australia, Crawley, WA 6009, Australia
| | - Andrew D Redfern
- School of Medicine, The University of Western Australia, Crawley, WA 6009, Australia
| | - K Swaminathan-Iyer
- School of Molecular Science, The University of Western Australia, Crawley, WA 6009, Australia
| | - Pilar Blancafort
- Cancer Epigenetics, Harry Perkins Institute of Medical Research Nedlands, WA 6009, Australia; School of Human Sciences, The University of Western Australia Crawley, WA 6009, Australia.
| |
Collapse
|